uli, including bacteria and their products.
1,2 IL-12 stimulates the proliferation and cytotoxic activity of natural killer (NK) cells and enhances generation of cytotoxic T cells (CTL). 3, 4 The powerful effect of IL-12 on production of interferon-␥ (IFN-␥) promotes the differentiation and growth of type 1 T helper (Th1) cells. 5, 6 It has been shown that IFN-␥ is an important cytokine in the efferent phase of acute graft-versus-host disease (GVHD) and that serum IFN-␥ is increased in patients with acute GVHD. 7 Th1 cytokines may be potent in stimulating cell-mediated immune mechanisms involved in acute GVHD. This hypothesis is supported by reports that localized production of IFN-␥ within acute GVHD-target organs is mediated by IL-12 production from M, 8 and that anti-IL-12 mAb blocks acute GVHD development in vivo in mice. 9, 10 However, the role of IL-12 in acute GVHD after human allogeneic BMT is not fully understood.
Prevention of GVHD by removal of T cells from donor BM inocula has been associated with increased rates of engraftment failure, leukemia relapse 11 and EBV-LPD. 12 The antileukemic reaction associated with allogeneic BMT is referred to as the graft-versus-leukemia (GVL) effect. GVHD and the GVL effect are intimately associated. 13 IL-12 has been shown to enhance the cytotoxicity of NK cells and CTL in vitro, and to augment the cytotoxicity of tumor infiltrating lymphocytes against autologous tumor cells in humans.
14 Studies using transplantable tumors in experimental animals have shown a dramatic effect of IL-12 in decreasing tumor growth and metastasis. 15 Decreased antileukemic immunity and risk of developing EBV-LPD in T cell-depleted BMT may be due to a defect in IL-12 production or poor response to IL-12.
In this study, we examined the role of IL-12 and IL-12-induced IFN-␥ production in the development of acute GVHD, GVL effects and EBV-LPD.
Materials and methods

Patients
A total of 24 Japanese patients, 16 males and 8 females, aged 6 months to 39 years received BMT from either HLAidentical siblings (two patients), HLA-matched unrelated donors (four patients) or HLA-mismatched related donors (18 patients). Twenty patients were transplanted for hematologic malignancies, two for congenital metabolic disease, one for pure red cell aplasia, and one for congenital immune deficiency. All patients achieved engraftment confirmed by various genetic markers including sex chromosomes, HLA typing, and DNA-restriction fragment length polymorphisms (RFLP). The grading of acute GVHD was determined as previously described, with grade 0 GVHD being observed in 14 patients, grade I in four, grades II-IV in six. Fourteen patients received positively selected CD34 marrow and/or peripheral blood cells 16 and three received T cell-depleted bone marrow achieved by ex vivo incubation with anti-CD5/8 monoclonal antibodies. 17 All patients had no additional clinical problems such as bacterial and viral infection at the point of collecting samples, but three patients developed EBV-LPD 3-5 months after the sampling. Patient characteristics are shown in Table 1 . Eight patients received positively selected CD34 marrow cells from two or three locus HLA-mismatched parents and received immunotherapy with DLT for treatment or prophylaxis of leukemia relapse and EBV-LPD 35 days to 23 months after BMT. Five DLT patients developed GVHD (grades I-III) and two of these patients entered complete remission following development of GVHD but three DLT patients with EBV-LPD did not develop acute GVHD. Table 2 presents the clinical characteristics and courses of the patients receiving DLT.
Isolation and stimulation of mononuclear cells
Peripheral blood was obtained 14-100 days post BMT and all sera were kept frozen at −20°C until analyzed. IFN-␥ production was followed in five cases with acute GVHD, including two cases of DLT, after resolution of acute GVHD. Peripheral blood mononuclear cells (PBMC) were alone, immobilized anti-CD3 mAb alone and with immobilized anti-CD3 mAb plus 20 U/ml of IL-12 for 48 h followed by determination of IFN-␥ production. Anti-CD3 mAb (OKT3) was immobilized in plastic plates by incubation of 96-well round-bottomed plates with 20 l of anti-CD3 mAb (50 g/ml) for 2 h at 37°C. In 10 of the 24 patients receiving allogeneic BMT and the eight patients receiving DLT, the adherent cells (1 × 10 5 cells/well) in the Petri dishes, which consisted of M as determined by morphology and non-specific esterase staining, were stimulated with 30 g/ml of LPS (Difco, Detroit, MI, USA) for 48 h followed by measurement of IL-12 production. After culture, each culture supernatant was harvested and kept frozen at −20°C.
Detection of IFN-␥ by ELISA
PBL obtained from BMT patients or healthy volunteers were stimulated with IL-12 alone or IL-12 plus immobilized CD3 mAb and IFN-␥ concentrations in the culture supernatants were measured by a sandwich ELISA technique (Biosource, Camarillo, CA, USA), as described in detail previously. All samples were run in triplicate and the sensitivity of the assay was Ͻ5.0 pg/ml.
Detection of IL-12 by ELISA
IL-12 protein concentrations in serum or culture supernatants from LPS-stimulated PBM of BMT patients and volunteers were measured by a sandwich ELISA technique (Biosource). All samples were run in triplicate and the sensitivity of the assay was Ͻ5.0 pg/ml.
Statistical analysis
Results are presented as the mean ± s.e.m. The significance of differences between two groups was determined using the nonparametric Wilcoxon test. Scheffe's F tests were used when comparing multiple groups. P values Ͻ0.05 were considered significant.
Results
IFN-␥ production by PBL of BMT patients
ELISA was performed to compare IFN-␥ production by PBL from BMT patients with acute GVHD with that of PBL from patients without GVHD and adult healthy volunteers. Unstimulated PBL from BMT patients and volunteers did not show detectable production of IFN-␥ (Ͻ10.0 pg/ml). IL-12 alone (20 U/ml) and immobilized anti-CD3 mAb alone (50 g/ml) induced a mild increase in IFN-␥ production from both PBL and BMT patients with and without acute GVHD and from volunteers (data not shown). However, IL-12 (20 U/ml) plus immobilized anti-CD3 mAb (50 g/ml) induced a significant increase in IFN-␥ production by PBL of BMT patients with acute GVHD and healthy adult volunteers. The IFN-␥ production induced by IL-12 plus anti-CD3 mAb was 239.7 ± 85.9 pg/ml (acute GVHD grade 0), 999.2 ± 125.4 pg/ml (grade I), 1346.2 ± 102.6 pg/ml (grades II-IV), and 1506.5 ± 353.5 pg/ml (healthy adult volunteers) (Figure 1 ). The level of IFN-␥ production increased in parallel with increasing severity of GVHD, and healthy adult volunteers had the same levels of IFN-␥ production as did grades II-IV GVHD patients. Decrease of IFN-␥ production was detected in five cases with acute GVHD after resolution of acute GVHD (56-329 pg/ml). 
IL-12 serum concentrations in allogeneic BMT patients
IL-12 concentrations in sera from BMT patients and six healthy volunteers were measured. IL-12 serum concentrations after allogeneic BMT, regardless of the presence of acute GVHD, were not significantly different from those observed in healthy volunteers (grade 0, 67.6 ± 74.2 pg/ml; grade I, 74.0 ± 50.3 pg/ml; grades II-IV, 41.0 ± 23.5 pg/ml; healthy adult volunteers, 14.3 ± 5.0 pg/ml).
IL-12 production by PBM from BMT patients
IL-12 concentrations in culture supernatants of PBM stimulated with LPS were determined after BMT. Four BMT patients with grades I, II acute GVHD produced significantly higher concentrations of IL-12 than six BMT patients without acute GVHD, healthy adult volunteers (grade 0, 522.0 ± 193.3 pg/ml vs grades I, II, 1367.5 ± 131.6 pg/ml; n = 6 vs 4, P = 0.01, and adult healthy volunteers: 303.8 ± 12.2 pg/ml) ( Figure 2 ). 
Relationship between GVHD/GVL and IL-12 after DLT
The relationship between IFN-␥ production, IL-12 production, and clinical data for eight patients receiving DLT after BMT are summarized in Table 3 . None of the eight patients had evidence of acute GVHD before DLT. Two patients had leukemia relapse after BMT and did not receive chemotherapy before or after DLT. Five patients receiving DLT for treatment or prophylaxis of leukemia relapse subsequently developed acute GVHD (grades I-III), and the production of IFN-␥ by PBL stimulated with IL-12 plus anti-CD3 mAb closely correlated with the clinical grade of acute GVHD. The production of IL-12 by PBM stimulated with LPS (30 g/ml) was also very high following DLT. Acute GVHD gradually subsided following the administration of immunosuppressive agents except in patient UPN 263, whose IFN-␥ production was not particularly high. The IFN-␥ and IL-12 production mentioned above also decreased with the resolution of acute GVHD. The number of PBL increased after DLT. Two patients with leukemic relapse entered complete remission following development of acute GVHD while three patients had no leukemic relapse. Patient UPN 225 suffered a second relapse and died of leukemia 6 months after DLT. Patients UPN 240 and 263 had severe cytomegalovirus infection and bacterial pneumonitis, respectively. These infections improved after DLT. Patient UPN 240 died of idiopathic interstitial pneumonitis 2 months after DLT. Three patients receiving DLT for treatment of EBV-LPD did not develop acute GVHD, and IFN-␥ and IL-12 production were also low. These patients died of B cell lymphoma.
Discussion
Allogeneic BMT is the established treatment for hematologic malignancies resistant to conventional chemotherapy. 18 Acute GVHD occurs in 40-85% of patients who receive allogeneic grafts, 19 and donor-derived T cells play an important role in the onset of GVHD. 20 They also play a pivotal role in the anti-leukemic effect of allogeneic BMT. 21 It has been suggested that most of the clinical manifestations of GVHD are due to cytokine dysregulation. 22 Previous studies have suggested a correlation between acute GVHD and high serum concentrations of tumor necrosis factor-␣ (TNF-␣), 23 IFN-␥ 7 and circulating IL-6. 24 Therefore, cytokine manipulation might be useful for the control of acute GVHD mediated by cellular immunity.
IL-12 is thought to play an important role in the regulation of the response to allogeneic BMT. IL-12 induces production of IFN-␥ and other lymphokines and causes inflammatory responses. Recent work indicates that IL-12 plays a central role in the polarization of Th cell-dependent responses. In vivo neutralization of endogenous IL-12 ameliorates acute GVHD in mice, in association with reduced splenic NK cell activity, IFN-␥ production, immunosuppression, weight loss, and mortality. Conversely, administration of exogenous murine rIL-12 exacerbates this disease. 10 IL-12 p40 peptide mRNA is increased in M purified from AxC57BL/6F1 mice with acute GVHD due to injection of C57BL/6 lymphoid cells. 8 The data presented here indicate that PBL from patients with acute GVHD after allogeneic BMT show a significant increase in IFN-␥ production as do those from healthy adult volunteers, when stimulated with IL-12 plus anti-CD3 mAb. IL-12 acts synergistically with IL-2, phorbol diesters, mitogenic lectins, and T cell receptor (TCR)/CD3 stimuli such as anti-CD3 antibodies in inducing T cell IFN-␥ production. 25 We speculate that IFN-␥ production by PBL is low in the patients after allogeneic BMT because of downregulation due to immunosuppressive treatment or dysfunction of cellular immunity, and that immobilized anti-CD3 mAb may enhance the production of IFN-␥ by stimulated IL-12-PBL from patients with acute GVHD to a greater degree than in patients without acute GVHD. Further studies suggest that IL-12 production by PBM stimulated with LPS is significantly higher in patients with acute GVHD compared to those without acute GVHD and healthy adult volunteers. These findings indicate that PBM from patients with acute GVHD is more responsive to LPS stimulation with respect to IL-12 production. Acute GVHD is thought to develop by a three-step process. 26 In phase 1, the conditioning regimen leads to damage and activation of host tissues and induces the secretion of the inflammatory cytokines, tumor necrosis factor (TNF)-␣ and interleukin (IL)-1. These cytokines increase expression of major histocompatibility complex (MHC) antigens and adhesion molecules, enhancing the recognition of host-MHC antigens by mature donor T cells after allogeneic BMT. Furthermore, injury to the mucosal surface of the gastrointestinal tract may lead to formation of bacterial breakdown products, such as LPS. LPS may subsequently stimulate splanchnic or circulating M to produce IL-12.
27 Donor T cell activation in phase 2 may be characterized by proliferation of Th 1 T cells stimulated by IL-12. The secretion of IL-2 and IFN-␥ from Th 1 cells induce T cell expansion and cytotoxic T lymphocytes (CTL) and NK cell responses, causing local tissue injury of the gut, liver and skin (phase 3). Our data indicate that IL-12 may be a key cytokine in this process and that activation of Th1 cells is responsible primarily for initiating acute GVHD. Significantly, in this study, five patients who received DLT for treatment or prophylaxis of leukemia relapse, developed grade I to III acute GVHD with high IFN-␥ production by PBL stimulated by IL-12 plus anti-CD3 mAb and high IL-12 production by M stimulated by LPS. However, the serum IL-12 concentrations were very low in the patients with acute GVHD, in agreement with a previous report. 28 The occurrence of GVHD after allogeneic BMT is not associated with increased serum IL-12 concentrations because of downregulation due to immunosuppressive agents. On the other hand, a single injection of murine rIL-12 inhibits acute GVHD in a fully MHC plus multiple minor antigen-mismatched BMT model (A/J-B10). 29 Although IL-12 can enhance T cell proliferation, a recent study has shown that high doses of IL-12 administered to mice can lead to depletion of splenic CD4
+ and CD8 + cells and can inhibit virus-specific CTL activity and CD8 + T cell expansion, 30 suggesting that IL-12 may inhibit the initial GVHD-associated T cell expansion and that the resulting delay in the GVH response may be sufficient to markedly delay the onset of clinical GVHD. The immune reactivity of allogeneic lymphocytes plays an important role in the control of leukemia after BMT, although GVHD is frequent among responders. Induction of an anti-tumor effect by GVL has been demonstrated for both experimental and clinical BMT. Allogeneic cell therapy may also be given effectively post transplantation by administration of allogeneic lymphocytes in graded increments, and allogeneic lymphocytes of donor origin can be given for both treatment and prevention of relapse, 31 especially in the case of T cell-depleted BMT patients. We have shown that two patients with hematologic relapse responded to DLT and one patient remained in complete remission, with increased IFN-␥ production by PBL stimulated with IL-12 plus anti-CD3-mAb and increased IL-12 production by PBM stimulated with LPS after DLT. These results imply that IL-12 may be a novel cytokine which facilitates the anti-leukemic effect of allogeneic donor lymphocytes. Recent observations suggest that antitumor effects induced by allogeneic lymphocytes can be increased further by in vivo activation of lymphocytes with recombinant human interleukin-2 (rhIL-2). 32 Moreover, our data show that patients with leukemia resistant to DLT can still respond to in vivo or in vitro activation of donor PBL by IL-12. Two patients with severe viral and bacterial infections also improved after DLT with increased IFN-␥ production by PBL stimulated with IL-12 plus anti-CD3-mAb and increased IL-12 production by PBM. Impaired immunity after T cell-depleted stem cell transplantation may contribute to a poor response of Th1 cells to IL-12. On the other hand, three DLT patients with EBV-LPD had no active GVHD without increase of IFN and IL-12 production before and after DLT. EBV is believed to be controlled by virus-specific cytotoxic T lymphocytes (CTL), and donor lymphocytes have been used to treat EBV-LPD. 33 Our data suggest that IL-12 may also play an important role in the control of EBV-LPD after allogeneic BMT. The reason why donor lymphocytes were not beneficial is probably due to the delay between presentation and confirmation of diagnosis.
In summary, the present study demonstrated that IFN-␥ production by PBL after stimulation with IL-12 plus anti-CD3 mAb and IL-12 production by PBM after LPS stimulation are increased in patients with acute GVHD. Five patients who received DLT after BMT for treatment or prophylaxis of leukemia relapse, all developed acute GVHD. IFN-␥ PBL production and IL-12 PBM production increased after DLT and two patients with leukemia relapse went into complete remission, while three DLT patients with EBV-LPD did not develop acute GVHD without increase of IFN-␥ and IL-12 production. These findings suggest that IL-12 may play an important role in the development of acute GVHD, the GVL effect and control of EBV-LPD after human allogeneic stem cell transplantation. We hypothesized that the administration of anti-IL-12 mAb may inhibit acute GVHD. Furthermore, exogenous IL-12 administration may compensate for the post-transplantation immune defects seen with T cell-depleted BMT and may be useful therapeutically in preventing early tumor recurrence.
Moreover, the level of IL-12 or IFN-␥ production in BMT patients may be a good factor for prediction of GVHD grade and control of EBV-LPD after BMT.
